Fang Hu, Chairman/CEO

Postdoctoral fellow, University of California San Francisco, USA. 

M.D., Shanghai Second Medical University.

Dr. Hu served as the CEO at Shanghai Sunway Biotech Co., LTD., and the visiting professor at Cancer Hospital Chinese Academy of Medical Science and Cancer Hospital Perking Union Medical College. Dr. Hu built the Sunway R&D team and accomplished H101(Oncorine®)'s bench-to-bed milestones.

Jinlu Cai, Board Member/General Manager

B.S. in Computer Science and Technology, Zhejiang University.

Ph.D. in Genetics, the University of Iowa, USA.

Dr. Cai served as a research faculty in the Albert Einstein College of Medicine and a senior bioinformatics scientist in Mount Sinai Medical Center. She has extensive experience in bioinformatics research and application to drug development.

Janie J Fu, CSO

Postdoctoral fellow, Columbia University, USA. 

M.D., Fujian Medical University

After finishing postdoctoral training at Columbia University, she started her academic research at University of California, Irvine, USA. Later, she served as the co-director of pre-clinical study at Kadmus Pharmaceutics, USA and the director of pharmacology department at Italia Institute of Technology, Genova, Italy. Dr. Fu has more than 15-year experience on upstream of drug discovery and pre-clinical studies.

Huiqun Xia，CMO

Expert in Medical Science

M.D., McGill University, CA

Served as Medical Director in Shanghai Sunway, Virogin, earlier medical fellow in Mount Sinai Medical Center (USA). 30+ years of experience in clinical studies and novel drug development including multiple OV products.

Can Chen, Vice President

B.S. in Biological Sciences, Zhejiang University

Ph.D. in Cancer Targeting Therapy, National University of Singapore 

Dr. Chen was the senior research scientist at Tessa Therapeutics in Singapore. She has long been engaged in cancer targeted therapy research, including neural stem cells, dendritic cells, and CAR-modified immune cell-mediated cancer-targeted therapies. She is good at the culture of various stem cells and primary immune cells, the preparation and functional validation of CAR-modified immune cells. She is dedicated to promoting the research, development, and clinical translation of CAR-modified immune cell therapy technology.

Yunfan Liu, Director of Biologics Development

M.D., National Institute for Viral Disease Control and Prevention of CDC.

Dr. Liu has had great experience in CMC of viral vectors, IND for immune cells agents such as CAR-T and DCs, as well as the large-scale cultivation and quality control of MSCs.

Jipo Sheng, Project Manager, Oncolytic Adenovirus

B.S. in Biochemistry, Lanzhou University

Ph.D. in molecular genetics, Beijing Institute of Biotechnology 

Postdoctoral fellows, the department of developmental and regenerative biology/the Cardiovascular Research Center, Mount Sinai School of Medicine, New York University.

Dr. Sheng focuses on the molecular mechanism research of cancer genesis and development for more than 10 years. He has solid theoretical and practical basis on molecular biology, especially profound experience on the preparation and application of Lentivirus, Adenovirus and Adeno-Associated Virus.

Jin Shi，IP Director

B.S. from Peking University (Beijing, China)

Ph.D. in Chemistry from University of Georgia (Georgia, USA)

Postdoctoral Research Fellow at Memorial Sloan-Kettering Cancer Center (New York, USA)

She holds a Patent Agent Qualification Certificate. She has many years of experience in providing IP analysis and assessment, and developing IP strategies.